Fig. 2From: Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trialPrimary outcome and secondary clinical outcome. ECMO extracorporeal membrane oxygenation, FiO2 fraction of inspired oxygen, LSMean Least Square Means, PaO2 partial pressure of arterial oxygenBack to article page